Kiora Pharmaceuticals, Inc. (KPRX)
NASDAQ: KPRX · Real-Time Price · USD
2.090
-0.010 (-0.48%)
At close: Feb 27, 2026, 4:00 PM EST
2.120
+0.030 (1.44%)
After-hours: Feb 27, 2026, 7:38 PM EST
Kiora Pharmaceuticals Employees
Kiora Pharmaceuticals had 12 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
12
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$711,845
Market Cap
7.67M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 117 |
| CollPlant Biotechnologies | 57 |
| Aptevo Therapeutics | 37 |
| Theriva Biologics | 22 |
| Moleculin Biotech | 17 |
| CalciMedica | 15 |
| Alzamend Neuro | 7 |
| Ernexa Therapeutics | 6 |
KPRX News
- 9 days ago - Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference - Newsfile Corp
- 4 weeks ago - Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board - Newsfile Corp
- 3 months ago - Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds - Newsfile Corp
- 4 months ago - Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases - Newsfile Corp
- 4 months ago - Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders - PRNewsWire
- 4 months ago - Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025 - Newsfile Corp
- 7 months ago - Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases - Newsfile Corp
- 7 months ago - Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease - Newsfile Corp